LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 10 of 15: Cell count and normalized growth rate inhibition values within biological replicate 3. - Dataset - HMS LINCS Database

LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 10 of 15: Cell count and normalized growth rate inhibition values within biological replicate 3. - Dataset (ID:20247)

Download: Excel (XLSX), Comma-separated (CSV)

<<<<

Select the entities to show:

Small molecules	Cells

|<
<<
Previous
Page 301 of 535
Next
>>
>
7501 to 7525 of 13356 records
per page:

Cell	Small Molecule	Small Mol Concentration	Small Mol Conc Unit	LJP Library Plate	Replicate	Assay Well	Timepoint	Timepoint Unit	Total Cell Count Before Treatment	Total Cell Count After Treatment	Total Control Cell Count	Relative Cell Count	Normalized Growth Rate Inhibition Value
BT-20	Barasertib	3.33	uM	LJP5	1	D08	72	hr	1097	1481	3735	0.3965	0.1850
BT-20	Barasertib	3.33	uM	LJP5	2	D08	72	hr	1097	1589	3877	0.4098	0.2255
BT-20	Barasertib	3.33	uM	LJP5	3	D08	72	hr	1097	1467	3925	0.3737	0.1711
BT-20	Barasertib	10	uM	LJP5	1	D07	72	hr	1097	1337	3735	0.3579	0.1183
BT-20	Barasertib	10	uM	LJP5	2	D07	72	hr	1097	979	3877	0.2525	-0.0607
BT-20	Barasertib	10	uM	LJP5	3	D07	72	hr	1097	1121	3925	0.2856	0.0117
BT-20	Vemurafenib	0.04	uM	LJP5	1	C18	72	hr	1097	3746	3735	1.0029	1.0033
BT-20	Vemurafenib	0.04	uM	LJP5	2	C18	72	hr	1097	3479	3877	0.8972	0.8843
BT-20	Vemurafenib	0.04	uM	LJP5	3	C18	72	hr	1097	3814	3925	0.9716	0.9689
BT-20	Vemurafenib	0.12	uM	LJP5	1	C17	72	hr	1097	3713	3735	0.9941	0.9933
BT-20	Vemurafenib	0.12	uM	LJP5	2	C17	72	hr	1097	3651	3877	0.9415	0.9349
BT-20	Vemurafenib	0.12	uM	LJP5	3	C17	72	hr	1097	3665	3925	0.9337	0.9267
BT-20	Vemurafenib	0.37	uM	LJP5	1	C16	72	hr	1097	3646	3735	0.9761	0.9728
BT-20	Vemurafenib	0.37	uM	LJP5	2	C16	72	hr	1097	3558	3877	0.9175	0.9077
BT-20	Vemurafenib	0.37	uM	LJP5	3	C16	72	hr	1097	3544	3925	0.9028	0.8919
BT-20	Vemurafenib	1.11	uM	LJP5	1	C15	72	hr	1097	3309	3735	0.8859	0.8675
BT-20	Vemurafenib	1.11	uM	LJP5	2	C15	72	hr	1097	3523	3877	0.9085	0.8974
BT-20	Vemurafenib	1.11	uM	LJP5	3	C15	72	hr	1097	3531	3925	0.8995	0.8881
BT-20	Vemurafenib	3.33	uM	LJP5	1	C14	72	hr	1097	3232	3735	0.8653	0.8428
BT-20	Vemurafenib	3.33	uM	LJP5	2	C14	72	hr	1097	3334	3877	0.8598	0.8408
BT-20	Vemurafenib	3.33	uM	LJP5	3	C14	72	hr	1097	3440	3925	0.8763	0.8615
BT-20	Vemurafenib	10	uM	LJP5	1	C13	72	hr	1097	2455	3735	0.6573	0.5772
BT-20	Vemurafenib	10	uM	LJP5	2	C13	72	hr	1097	2444	3877	0.6303	0.5522
BT-20	Vemurafenib	10	uM	LJP5	3	C13	72	hr	1097	2393	3925	0.6096	0.5281
BT-20	Enzastaurin	0.04	uM	LJP5	1	D18	72	hr	1097	3729	3735	0.9983	0.9981

|<
<<
Previous
Page 301 of 535
Next
>>
>
7501 to 7525 of 13356 records
per page:

HMS LINCS Project

LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 10 of 15: Cell count and normalized growth rate inhibition values within biological replicate 3. - Dataset (ID:20247)